

HitGen with Janssen to build novel DNA-Encoded Libraries

10 December 2019 | News

To discover unique small molecule assets



China based HitGen Inc. is pleased to announce that the company has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to design and build novel DNA-encoded libraries (DELs) to discover unique small molecule assets.

The collaboration will apply HitGen's advanced technology platform and research capabilities in the design and synthesis of multiple proprietary DELs for Janssen drug discovery and development efforts. The collaboration was facilitated by Johnson & Johnson Innovation and builds upon the success of earlier agreements for the identification of hits using HitGen's platform for various priority targets.

"We look forward to working closely with Janssen to design and build proprietary DELs to support the discovery of a new generation of medicines to address unmet clinical challenges. This collaboration reflects HitGen's capabilities, expertise, and flexibility to develop business models to meet the needs of our collaboration partners and reflects insight into the success of our initial target-based collaboration," said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen.